Defence's Proprietary Accum Technology Ready to License to Companies Developing Antibody Drug Conjugates (ADC)
Defence Therapeutics announces plans to license its proprietary Accum® technology to pharmaceutical companies developing Antibody Drug Conjugates (ADCs). The technology enhances the delivery and efficacy of biologics by overcoming endosomal entrapment, potentially increasing therapeutic potency and reducing dosing requirements. The company aims to generate revenue through licensing while establishing its technology as an industry standard. Additionally, Defence completed a private placement, issuing 50,000 units at $0.50 per unit for proceeds of $25,000, and amended terms for 1,497,780 warrants, reducing their exercise price from $1.75 to $0.75.
Defence Therapeutics annuncia piani per concedere in licenza la propria tecnologia Accum® alle aziende farmaceutiche che sviluppano Antibody Drug Conjugates (ADC). Questa tecnologia migliora la somministrazione e l'efficacia dei biologici superando la cattura endosomiale, aumentando potenzialmente la potenza terapeutica e riducendo i requisiti di dosaggio. L'azienda punta a generare entrate tramite concessioni in licenza, mentre stabilisce la propria tecnologia come standard del settore. Inoltre, Defence ha completato un collocamento privato, emettendo 50.000 unità a $0,50 per unità, per un ricavato di $25.000, e ha modificato i termini di 1.497.780 warrants, riducendo il loro prezzo di esercizio da $1,75 a $0,75.
Defence Therapeutics anuncia planes para licenciar su tecnología propietaria Accum® a empresas farmacéuticas que desarrollan Antibody Drug Conjugates (ADC). Esta tecnología mejora la entrega y eficacia de los biológicos al superar la captura endosomal, lo que potencialmente aumenta la potencia terapéutica y reduce los requerimientos de dosificación. La empresa tiene el objetivo de generar ingresos a través de licencias, mientras establece su tecnología como un estándar en la industria. Además, Defence completó una colocación privada, emitiendo 50,000 unidades a $0.50 por unidad, obteniendo ingresos de $25,000, y modificó los términos de 1,497,780 warrants, reduciendo su precio de ejercicio de $1.75 a $0.75.
Defence Therapeutics는 항체-약물 접합체(ADC)를 개발하는 제약 회사에 독점 Accum® 기술을 라이선스 하려는 계획을 발표했습니다. 이 기술은 엔도좀 포획을 극복하여 생물학적 제제를 효과적으로 전달하고 효능을 향상시켜, 치료 효과를 높이고 투여 요구 사항을 줄일 수 있습니다. 이 회사는 라이선스를 통해 수익을 창출하고, 자사의 기술을 업계 표준으로 정립함을 목표로 하고 있습니다. 또한, Defence는 50,000 단위를 유가증권으로 발행하여 단위당 $0.50에 총 $25,000의 수익을 올렸으며, 1,497,780 개의 워런드의 조건을 수정하여 운동 가격을 $1.75에서 $0.75로 낮추었습니다.
Defence Therapeutics annonce des plans pour accorder sous licence sa technologie propriétaire Accum® à des entreprises pharmaceutiques développant des Antibody Drug Conjugates (ADC). Cette technologie améliore la livraison et l'efficacité des biologiques en surmontant l'emprisonnement endosomal, ce qui augmente potentiellement la puissance thérapeutique et réduit les besoins en dosage. L'entreprise vise à générer des revenus grâce à la concession de licences tout en établissant sa technologie comme norme dans l'industrie. De plus, Defence a complété un placement privé en émettant 50 000 unités à 0,50 $ l'unité, pour un produit de 25 000 $, et a modifié les termes de 1 497 780 warrants, réduisant leur prix d'exercice de 1,75 $ à 0,75 $.
Defence Therapeutics kündigt Pläne an, seine proprietäre Accum®-Technologie an Pharmaunternehmen zu lizenzieren, die Antibody Drug Conjugates (ADCs) entwickeln. Die Technologie verbessert die Lieferung und Wirksamkeit von biologischen Arzneimitteln, indem sie endosomale Einschlüsse überwindet, was potenziell die therapeutische Wirksamkeit erhöht und die Dosierungsanforderungen verringert. Das Unternehmen zielt darauf ab, Einnahmen durch Lizenzen zu generieren und seine Technologie als Branchenstandard zu etablieren. Darüber hinaus hat Defence eine Privatplatzierung abgeschlossen und 50.000 Einheiten zu je $0,50 ausgegeben, was Einnahmen von $25.000 generiert, und hat die Bedingungen für 1.497.780 Warrants geändert, wobei der Ausübungspreis von $1,75 auf $0,75 gesenkt wurde.
- New revenue stream potential through licensing Accum® technology
- Completed private placement raising $25,000 in additional capital
- Warrant exercise price reduced from $1.75 to $0.75, indicating potential share price pressure
- Small size of private placement ($25,000) suggests investor interest
Vancouver, British Columbia--(Newsfile Corp. - November 29, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce its plan to license its proprietary Accum® technology to pharma and biotech companies developing Antibody Drug Conjugates ("ADCs") to amplifying their ADC potency and potentially reducing the dosing.
Defence operates on an innovative business model centered around its proprietary Accum® technology, a platform designed to significantly enhance the delivery and efficacy of biologics, including ADCs, radiopharmaceuticals, vaccines, and protein therapeutics. The Accum® technology optimizes intracellular delivery of therapeutic agents by overcoming endosomal entrapment, a common limitation in drug delivery systems. This enhancement can increase the potency and effectiveness of therapies, particularly in oncology and immunotherapy applications. By partnering with pharmaceutical and biotechnology companies, Defence positions itself as a key player in improving the therapeutic index of existing and developmental drugs, accelerating their journey to clinical success.
Defence plans to generate revenue by licensing its proprietary Accum® technology to companies developing ADCs, which are highly targeted cancer therapies. This strategy provides a dual benefit: it allows the Company to secure immediate revenue streams while establishing its technology as an industry standard in the ADC development process. Longer-term growth will be driven by expanding the applications of Accum® into other therapeutic areas, such as radiopharmaceuticals, vaccines and protein-based treatments, as well as pursuing proprietary drug development programs. This balanced approach ensures a sustainable revenue model, combining near-term potential profitability with long-term innovation and market expansion.
The Company wishes also to announce that, further to the 1st tranche closing on October 30th, 2024 of its previously announced non-brokered private placement of units of the Company at a price of
The Company announces an amendment to the terms of 1,497,780 Class A Common share purchase warrants (the "Warrant") originally issued as part of a non-brokered private placement of the Company that closed on November 16, 2022. The Warrants were subsequently amended on April 5, 2024. The exercise price of the Warrants will be repriced at
| Number of Warrants: | Previous Exercise Price of Warrants: | New Exercise Price of Warrants: |
| 1,497,780 |
All other terms of the Warrants will remain unchanged and are subject to the terms and conditions as outlined in the corresponding certificate of Warrant and the policies of the Canadian Securities Exchange.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232003
FAQ
What is Defence Therapeutics (DTCFF) planning to license to pharmaceutical companies?
How much did Defence Therapeutics (DTCFF) raise in its latest private placement?
What is the new exercise price for Defence Therapeutics (DTCFF) warrants issued in November 2022?
